TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PEARL Intervention to Reduce Depression Among Adults With Epilepsy
Brief Summary: The purpose of this study is to test the effectiveness of a home-based depression treatment intervention called "Program to Encourage Active, Rewarding Lives (PEARL)". We hypothesize that over a 12-month period, compared to usual care, those receiving the PEARL intervention will show more improvement with their depression, have higher quality of life and function, and use fewer medical services.


Options:
A: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
B: Arm Label: Depression Care Management; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: Care as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Depression Care Management
C: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PEARL Intervention to Reduce Depression Among Adults With Epilepsy
Brief Summary: The purpose of this study is to test the effectiveness of a home-based depression treatment intervention called "Program to Encourage Active, Rewarding Lives (PEARL)". We hypothesize that over a 12-month period, compared to usual care, those receiving the PEARL intervention will show more improvement with their depression, have higher quality of life and function, and use fewer medical services.


Options:
A: Arm Label: physical activity and nutrition; Type: EXPERIMENTAL; Interventions: Behavioral: Project Fit | Intervention Type: BEHAVIORAL; Name: Project Fit; Assigned to Arm(s): physical activity and nutrition
B: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: interdisciplinary intervention or meeting-seminars | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interdisciplinary intervention or meeting-seminars | Intervention Type: BEHAVIORAL; Name: interdisciplinary intervention or meeting-seminars; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: In-school Sexual Health Education; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth-friendly health services; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth condom promotion & distribution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Community activities related to adolescent sexual health; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence Feedback for Improving Respiratory Medication Use
Brief Summary: The purpose of this study is to determine whether providing patient medication adherence information on inhaled corticosteroid use to clinicians will result in improved patient adherence and asthma control.


Options:
A: Arm Label: Concealment (control); Type: OTHER; Interventions: Device: MedSignals pillbox | Arm Label: Disclosure (intervention); Type: EXPERIMENTAL; Interventions: Behavioral: Disclosure of adherence report to clinician, Device: MedSignals pillbox | Intervention Type: BEHAVIORAL; Name: Disclosure of adherence report to clinician; Assigned to Arm(s): Disclosure (intervention) | Intervention Type: DEVICE; Name: MedSignals pillbox; Assigned to Arm(s): Concealment (control), Disclosure (intervention)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ibandronate [Bonviva/Boniva] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ibandronate [Bonviva/Boniva] | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 2
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
D: Arm Label: TEAM Care; Type: EXPERIMENTAL; Interventions: Behavioral: Pharmacy TEAM monitoring and counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pharmacy TEAM monitoring and counseling; Assigned to Arm(s): TEAM Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence Feedback for Improving Respiratory Medication Use
Brief Summary: The purpose of this study is to determine whether providing patient medication adherence information on inhaled corticosteroid use to clinicians will result in improved patient adherence and asthma control.


Options:
A: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo
B: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
D: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence Feedback for Improving Respiratory Medication Use
Brief Summary: The purpose of this study is to determine whether providing patient medication adherence information on inhaled corticosteroid use to clinicians will result in improved patient adherence and asthma control.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Web-based Asthma Management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based asthma education | Intervention Type: BEHAVIORAL; Name: Tailored Web-based Asthma Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Generic web-based asthma education; Assigned to Arm(s): 2
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Paper Asthma Action Plan; Type: EXPERIMENTAL; Interventions: Other: Paper Asthma Action Plan | Arm Label: Mobile Phone; Type: EXPERIMENTAL; Interventions: Device: Mobile Phone | Intervention Type: OTHER; Name: Paper Asthma Action Plan; Assigned to Arm(s): Paper Asthma Action Plan | Intervention Type: DEVICE; Name: Mobile Phone; Assigned to Arm(s): Mobile Phone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence Feedback for Improving Respiratory Medication Use
Brief Summary: The purpose of this study is to determine whether providing patient medication adherence information on inhaled corticosteroid use to clinicians will result in improved patient adherence and asthma control.


Options:
A: Arm Label: mailed information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: mailed information | Arm Label: community health worker; Type: EXPERIMENTAL; Interventions: Behavioral: community health worker | Intervention Type: BEHAVIORAL; Name: community health worker; Assigned to Arm(s): community health worker | Intervention Type: BEHAVIORAL; Name: mailed information; Assigned to Arm(s): mailed information
B: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
D: Arm Label: Feedback and alarms; Type: EXPERIMENTAL; Interventions: Device: Activated Smartinhaler or Smartturbo, Other: Feedback of adherence data | Arm Label: No feedback or alarms; Type: ACTIVE_COMPARATOR; Interventions: Device: Deactivated Smartinhaler or Smartturbo | Intervention Type: DEVICE; Name: Activated Smartinhaler or Smartturbo; Assigned to Arm(s): Feedback and alarms | Intervention Type: OTHER; Name: Feedback of adherence data; Assigned to Arm(s): Feedback and alarms | Intervention Type: DEVICE; Name: Deactivated Smartinhaler or Smartturbo; Assigned to Arm(s): No feedback or alarms

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg
Brief Summary: The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatment.


Options:
A: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
B: Arm Label: IFNB-1b 500 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg*; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 500 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg*
C: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zinc and Bone Metabolism in Thalassemia
Brief Summary: The purpose of this study is to test whether zinc can improve bone health in young patients with thalassemia.


Options:
A: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
B: Arm Label: Denosumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo Capsule; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Zinc (25 mg/d); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Zinc (25 mg/d) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo Capsule
D: Arm Label: Neridronato; Type: EXPERIMENTAL; Interventions: Drug: Neridronate | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neridronate; Assigned to Arm(s): Neridronato

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation
Brief Summary: Patients presenting for elective surgery requiring orotracheal intubation will be randomized to being intubated with either the conventional (reusable) GlideScope videolaryngoscope or the single-use GlideScope videolaryngoscope. The primary outcome is time to intubation.


Options:
A: Arm Label: Laryngoscopy; Type: OTHER; Interventions: Procedure: Endotracheal Intubation | Arm Label: Videolaryngoscopy; Type: OTHER; Interventions: Procedure: Endotracheal Intubation | Intervention Type: PROCEDURE; Name: Endotracheal Intubation; Assigned to Arm(s): Laryngoscopy | Intervention Type: PROCEDURE; Name: Endotracheal Intubation; Assigned to Arm(s): Videolaryngoscopy
B: Arm Label: Intubation c McGrath videolaryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: McGrath | Arm Label: Intubation using Macintosh Laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: Tracheal intubation using Macintosh Laryngoscope | Intervention Type: DEVICE; Name: McGrath; Assigned to Arm(s): Intubation c McGrath videolaryngoscope | Intervention Type: DEVICE; Name: Tracheal intubation using Macintosh Laryngoscope; Assigned to Arm(s): Intubation using Macintosh Laryngoscope
C: Arm Label: Truview EVO2®; Type: ACTIVE_COMPARATOR; Interventions: Other: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes | Arm Label: Airtraq®; Type: ACTIVE_COMPARATOR; Interventions: Other: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes | Arm Label: Direct laryngoscopy; Type: ACTIVE_COMPARATOR; Interventions: Other: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes | Intervention Type: OTHER; Name: Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes; Assigned to Arm(s): Airtraq®, Direct laryngoscopy, Truview EVO2®
D: Arm Label: Conventional Glidescope; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional (reusable) Glidescope | Arm Label: Single-use Glidescope; Type: EXPERIMENTAL; Interventions: Device: Single-use Glidescope videolaryngoscope | Intervention Type: DEVICE; Name: Conventional (reusable) Glidescope; Assigned to Arm(s): Conventional Glidescope | Intervention Type: DEVICE; Name: Single-use Glidescope videolaryngoscope; Assigned to Arm(s): Single-use Glidescope

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet, Exercise and Breastfeeding Intervention (DEBI) Program for Women With Gestational Diabetes
Brief Summary: The primary aim of this study is to evaluate whether a lifestyle intervention of diet, exercise, and breastfeeding is associated with decreased postpartum weight retention and reduced plasma glucose levels, measured at 6-weeks and 1-year postpartum, among women with gestational diabetes mellitus (GDM). Secondary outcomes are postpartum levels of plasma insulin, markers of insulin resistance, adiponectin, dietary fat, physical activity, and breastfeeding duration.


Options:
A: Arm Label: implementation strategy; Type: EXPERIMENTAL; Interventions: Other: implementation strategy of Breastfeeding | Arm Label: Conventional intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: implementation strategy of Breastfeeding; Assigned to Arm(s): implementation strategy
B: Arm Label: relaxation meditation tape; Type: EXPERIMENTAL; Interventions: Behavioral: Relaxation meditation tape | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Relaxation meditation tape; Assigned to Arm(s): relaxation meditation tape
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet, Exercise and Breastfeeding Intervention (DEBI) Program for Women With Gestational Diabetes
Brief Summary: The primary aim of this study is to evaluate whether a lifestyle intervention of diet, exercise, and breastfeeding is associated with decreased postpartum weight retention and reduced plasma glucose levels, measured at 6-weeks and 1-year postpartum, among women with gestational diabetes mellitus (GDM). Secondary outcomes are postpartum levels of plasma insulin, markers of insulin resistance, adiponectin, dietary fat, physical activity, and breastfeeding duration.


Options:
A: Arm Label: A - GWL; Type: EXPERIMENTAL; Interventions: Behavioral: Group weight loss program | Arm Label: B - GWL+SWA; Type: EXPERIMENTAL; Interventions: Other: Group weight loss program plus use of the Senseware Armband | Arm Label: C - SWA Alone; Type: EXPERIMENTAL; Interventions: Device: Use of the senseware armband alone program | Arm Label: D - Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group weight loss program; Assigned to Arm(s): A - GWL | Intervention Type: OTHER; Name: Group weight loss program plus use of the Senseware Armband; Assigned to Arm(s): B - GWL+SWA | Intervention Type: DEVICE; Name: Use of the senseware armband alone program; Assigned to Arm(s): C - SWA Alone
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
C: Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increase in activity to control weight.; Assigned to Arm(s): N/A
D: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diet, Exercise and Breastfeeding Intervention (DEBI) Program for Women With Gestational Diabetes
Brief Summary: The primary aim of this study is to evaluate whether a lifestyle intervention of diet, exercise, and breastfeeding is associated with decreased postpartum weight retention and reduced plasma glucose levels, measured at 6-weeks and 1-year postpartum, among women with gestational diabetes mellitus (GDM). Secondary outcomes are postpartum levels of plasma insulin, markers of insulin resistance, adiponectin, dietary fat, physical activity, and breastfeeding duration.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
C: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Proactive assignment to attend a breastfeeding clinic; Assigned to Arm(s): N/A

Answer: B